Categories: BioTechEngineeringInvestmentMedtech
Regcell Co., Ltd., founded in January 2016, aims to develop novel therapeutic technologies for autoimmune diseases, graft-versus-host disease, allergy and cancer through augmenting or suppressing immune responses by targeting regulatory T (Treg) cells.
Tregs actively maintain immune homeostasis by suppressing abnormal or excessive immune responses to self and foreign antigens.
Two projects are currently in progress. One is a Treg cell therapy by converting disease-mediating T cells into functionally stable Treg cells in vitro to treat autoimmune and other inflammatory diseases. The other is to explore small compounds that are specifically able to deplete Treg cells in tumor tissues and thereby enhance anti-cancer immunity.
Investors 2
Mentions in press and media 1
Reviews 0
